DENVER–(BUSINESS WIRE)–HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its OTC Topical Products have ranked number one in both sales dollars and units sold at a major Food & Drug Mass (“FDM”) retailer according to a recent NielsenIQ share report.
“Ranking #1 across all measured data, including #1 in sales by dollar volume and #1 by SKU volume, is a tremendous honor. Consumers are validating our team’s mission of providing best in class products that adhere to the highest standards of regulatory compliance,” commented Jason Mitchell, N.D., the Company’s Co-Founder and Chief Executive Officer. “Since its inception in 2015, HempFusion’s goal has been to develop and provide consumers with the highest quality products on the market, without compromise. We are meticulous in sourcing the right raw materials, ingredients, and delivery methods to help consumers live a more balanced lifestyle, and the FDM channel provides us with an unprecedented distribution opportunity to help us reach those consumers,” continued Dr. Mitchell.
The FDM channel represents the largest sales opportunity for the Company’s products by dollar volume. According to Brightfield Group, in Q3, 2020, 41% of CBD consumers reported they recently started shopping in-store again for products that contain CBD; and CBD specialty retailers and pharmacies saw an uptick in consumer-reported purchasing. HempFusion looks forward to leveraging this initial FDM channel success with other major retailers across the United States and abroad.
“The Food & Drug Mass channel has been a significant focal point of HempFusion’s strategic distribution plan, and to see our products quickly become the top-selling CBD brand according to NielsonIQ, in this entire Top 5 FDM Grocery retail chain, is incredibly exciting,” commented Jon Visser, the Company’s Chief Revenue Officer. “This third-party data demonstrates that our overall strategy of producing premium products with a focus on regulatory compliance, consumer messaging, and the right price point is resonating very well with category shoppers. We believe this is just the beginning. We are in continued talks with other top FDM retailers both domestically and internationally to ensure this data is widely available,” continued Visser.
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA Drug Listed Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the US Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex™ and are available in-store or by visiting HempFusion online at www.hempfusion.com or www.probulin.com.
Follow HempFusion on Twitter, Facebook and Instagram and Probulin on Twitter, Facebook and Instagram.
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“) that relate to HempFusion’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward-looking statements relating to the Company’s plans to leverage FDM sales, the Company’s broader retail distribution plans and the Company’s other plans, focus and objectives.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond HempFusion’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under “Forward-Looking Statements” and “Risk Factors” in the final long form prospectus of the Company dated December 17, 2020 and available under the Company’s profile on SEDAR at www.sedar.com. HempFusion undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for HempFusion to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.